The Art Of Creative Deal Making
This article was originally published in Scrip
Executive Summary
A challenging entry to 2016, with biotech's stock fallout, IPO struggles and the pharma industry's instability because of increasing global pricing woes and shifting business models, has put a spotlight on the industry to be more creative. As such, the topic of how to get adventurous in deal making shaped a lively debate at the recent European Life Science CEO forum in Zurich, Switzerland.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.